Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

Executive Summary

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.

You may also be interested in...



Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Celgene and Biogen are investing in the challenging therapeutic area, fueled by advances in science, growing understanding of the role inflammation may play in neurodegenerative diseases and improved tools for measuring efficacy.

GeNeuro’s Causal Approach To MS Treatment Gathers Momentum

GeNeuro is making good progress on its mid-stage clinical compound that is tackling a potential cause of multiple sclerosis. An early collaboration with Servier puts the Swiss biotech on a good footing if an ongoing Phase IIb trial – due to report interim data at the end of next year – is successful.

Biogen Anti-LINGO MS Study Failure Removes Upside

Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel